Clinical trials
Cirrhosis clinical trials
Below are recruiting cirrhosis clinical trials, each written for real people, not researchers. We’re tracking 261 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07799948Recruiting
Stent adjustment for repeated confusion after liver shunt
This study tests a procedure to narrow a stent in the liver to reduce episodes of confusion caused by toxins reaching the brain. It may help people who still have frequent confusion despite standard treatments.
Xi'an, ShaanxiAges 18 years+ - NCT07715500Recruiting
MRI of Bile Ducts in Living Liver Donors
This study uses an MRI scan to look at the bile ducts in healthy people who want to donate part of their liver. The goal is to see if the scan can help predict and prevent bile duct problems for the person receiving the liver.
New DelhiAges 18–55 - NCT07701993RecruitingPhase 3
Testing efimosfermin for MASH with compensated cirrhosis
This trial tests whether efimosfermin, an experimental drug, can safely help people with MASH (a fatty liver disease) that has led to cirrhosis (liver scarring) but the liver is still working well (compensated). Participants will be randomly assigned to receive the drug or a placebo.
Little Rock, ArkansasAges 18–75 - NCT07704892RecruitingPhase 3
Study of efimosfermin for adults with cirrhosis from MASH
This trial tests a new drug, efimosfermin, to see if it is safe and effective for people with cirrhosis caused by MASH (a type of fatty liver disease). It may help improve liver health compared to a placebo.
Little Rock, ArkansasAges 18–75 - NCT07685353Recruiting
Genes and graft fat after liver transplant study
This study looks at how genetic differences between liver donors and recipients affect fat buildup in the new liver after transplantation. It may help doctors understand why some transplanted livers develop steatosis (fatty liver) after the surgery.
New DelhiAges 18 years+ - NCT07610837RecruitingPhase 2
Testing AZD2389 for fatty liver disease with scarring
This study tests whether a new drug called AZD2389 is safe and well-tolerated in adults with steatotic liver disease (fatty liver) that has progressed to advanced scarring. The trial aims to see if this drug might help slow or improve liver damage in people with this condition.
Chandler, ArizonaAges 18 years+ - NCT07598669Recruiting
Austrian Primary Biliary Cholangitis Registry Study
This is a registry study that collects health information from people with primary biliary cholangitis (PBC), a rare liver disease where the immune system damages bile ducts. By joining, you help researchers better understand PBC and improve care for patients with this condition.
Klagenfurt, CarinthiaAges 18 years+ - NCT06338215Recruiting
Moderate drinking vs. abstention advice for adults
This study compares two approaches for adults who drink regularly: advice on drinking in moderation vs. advice to stop drinking entirely. The goal is to see which approach better prevents major diseases and early death over time.
Pamplona, NavarreAges 50–75 - NCT07561138Recruiting
Nutrition and Exercise Training Before Liver Transplant
This study tests whether eating better and doing gentle exercise before your liver transplant can help you stay healthier and recover better after surgery. You'll work with a nutrition expert and exercise specialist to prepare your body for transplant.
Athens, AtticaAges 18–70 - NCT06767579Recruiting
Comparing Delirium Risk After Liver Transplant: Inhaled vs. IV Anesthesia
This study compares how often confusion (delirium) happens after liver transplant when using two different anesthesia medicines: sevoflurane (inhaled gas) versus propofol (IV medicine). It helps doctors find out which anesthesia might be safer for your brain.
SeoulAges 19 years+ - NCT04073290RecruitingPhase 4
Rifaximin and lactulose to prevent confusion after TIPS
This trial studies whether taking rifaximin plus lactulose can prevent a brain problem called hepatic encephalopathy (confusion) after TIPS, a procedure to reduce pressure in the liver. It may help people who are having TIPS planned and are at risk of this complication.
LeuvenAges 18–80 - NCT07461532Recruiting
Apixaban for late portal vein clot after spleen surgery
This trial is testing whether a blood thinner called apixaban can treat a blood clot in the main vein to the liver (portal vein) that appeared more than a year after spleen surgery in people with cirrhosis. It compares apixaban to a low-dose aspirin to see if one works better with fewer side effects.
Yangzhou, JiangsuAges 18 years+ - NCT07461545Recruiting
Apixaban for late portal vein clot after spleen surgery
This trial tests if apixaban, a blood thinner, is more effective than aspirin at treating blood clots in the portal vein that form more than a year after laparoscopic spleen removal in people with cirrhosis and an enlarged spleen.
Yangzhou, JiangsuAges 18 years+ - NCT07462091Recruiting
Nerve-guided surgery for enlarged spleen and bleeding risk
This study tests a special surgery using a nerve-guided technique to remove the enlarged spleen and reduce bleeding risk in people with cirrhosis and portal hypertension. It may help if you have an enlarged spleen and have had bleeding related to liver disease.
Yangzhou, JiangsuAges 18 years+ - NCT07439939Recruiting
Blood Clotting Study in Cirrhosis Patients Getting a TIPS
This study looks at blood clotting in patients with cirrhosis who are getting a TIPS—a tube placed in the liver to help blood flow. The study aims to understand how the procedure affects bleeding and clotting, which could help make it safer for people with liver disease.
VillejuifAges 18 years+ - NCT07429864Recruiting
Bulevirtide for hepatitis D: bile acids and gut bacteria
This study looks at how Bulevirtide, a treatment for hepatitis D, affects bile acids and gut bacteria. It may help patients with chronic HDV and stable liver disease who are already on HBV therapy.
RomaAges 18 years+ - NCT07424963Recruiting
Comparing two ways to measure liver pressure
This study compares a newer, less invasive method using an endoscope (EUS-PPG) with a standard catheter method (HVPG) to measure liver pressure in people with advanced liver disease. The goal is to see if the newer method is equally accurate and safer.
Prague, BohemiaAges 18–75 - NCT06594783RecruitingPhase 4
Preventing varices bleeding with carvedilol and banding
This trial tests whether adding endoscopic banding helps prevent bleeding from enlarged varices in people with cirrhosis who still have high-risk varices despite taking carvedilol.
TaipeiAges 18–90 - NCT07414095Recruiting
Frailty assessment before liver transplant and outcomes
This study looks at how frail liver transplant candidates are before surgery and whether that affects their recovery afterward. Participants will complete simple physical and mental tasks to help doctors better understand their overall health before the transplant.
IzmirAges 18–65 - NCT07390344Recruiting
Study of VIATORR TIPS device for liver pressure
This study tests a new version of a device (VIATORR TIPS) that helps lower high blood pressure in the liver for people with cirrhosis. The device is placed to create a small channel that reroutes blood flow and reduces pressure.
Atlanta, GeorgiaAges 18 years+ - NCT06829290Recruiting
How muscle loss affects disease course in GI cancers
This study looks at how loss of muscle mass (sarcopenia) affects the course of illness in people with gastrointestinal cancers, liver cirrhosis, or those in the ICU. It will help doctors better understand and treat muscle wasting.
Mainz, Rhineland-PalatinateAges 18 years+ - NCT07393074Recruiting
Liver cancer and nervous system study
This study looks at how the nervous system works in people with liver cancer (hepatocellular carcinoma) or liver scarring (cirrhosis) who need a liver biopsy. It aims to see if there is a link between the nervous system and liver tumors.
LyonAges 18 years+ - NCT06293378Recruiting
Sulfasalazine for liver fibrosis and cirrhosis
This study tests if sulfasalazine, a medicine already used for other conditions, is safe and helpful for people with liver scarring (fibrosis or cirrhosis). It is for patients with cirrhosis caused by certain liver diseases, like PBC, hepatitis B, hepatitis C, or alcohol use.
Chongqing, Chongqing MunicipalityAges 18–70 - NCT07347275Recruiting
Liver dialysis for severe acute-on-chronic liver failure
This trial tests a new liver dialysis device called DIALIVE 2.0 for people with acute-on-chronic liver failure (a sudden, severe worsening of chronic liver disease). If you qualify, the device will help filter your blood, similar to kidney dialysis, to support your liver while it tries to recover.
London, Greater LondonAges 18–70
Hear when a new Cirrhosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for cirrhosis?
- Yes. Clin2 currently lists 261 recruiting cirrhosis studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a cirrhosis trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a cirrhosis trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.